BioMed Technology Holdings
Hong Kong microbiome startup and HKSTP partner offering precision microbiome testing and probiotic products — and expanding into oral and skin microbiomes, the axis closest to Coolvex's topical-care focus.
- Location
- Hong Kong Science Park, Pak Shek Kok · Hong Kong
- Visit window
- Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
- Source status
- medium confidencecandidate
Next action
Prepare the private outreach route and meeting ask; keep contact details out of the app.
Why now: Visit window · Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
What they do
Established 2018, develops precision-medicine-based microbiome testing services and probiotic products. It holds one of Hong Kong's largest microbiome databases (10,000+ profiles) and is extending R&D from gut into oral and skin microbiomes as part of a 'total microbiome solution'.
It is a Hong Kong Science and Technology Parks (HKSTP) partner company.
Why it matters
The only candidate explicitly building toward the skin microbiome — directly adjacent to Pure Advance's secondary Coolvex topical-care line. Its precision-testing + probiotic-product model and large microbiome dataset are relevant to consumer functional-health and skin-care R&D, and to strain/data collaboration or co-development.
Little tie to the agri-biocontrol lead, so value is data/strain/co-development on the Coolvex side; accessible as an HKSTP startup and plausibly deal-relevant at Pure Advance's scale.
Visit objective & route
Open a substantive R&D / data / skin-microbiome conversation for the Coolvex line, exploring data/strain collaboration or co-development and the maturity of the skin program.
Approach route
Appointment-only; route in via an HKSTP ecosystem introduction and pair with an HKSTP day (Insilico / AilsynBio / GenieBiome). Avoid Jul 8-10, LEAP East.
Talking points
- How mature is the skin-microbiome program (research vs product), and is it ready for a topical-care collaboration?
- Do you license data / strains or co-develop with consumer brands, and would your 10,000+-profile dataset support skin-care R&D?
- Is there any GCC / international interest, and what is the right route in via HKSTP?
- Bring the Pure Advance one-pager and an NDA template.
Open questions
- Leadership identities and the exact HK Science Park unit / office.
- Maturity of the skin-microbiome program (research vs product) and whether they license data/strains or co-develop with consumer brands.
- Current funding stage beyond the 2023 seed, and any GCC/international interest.
Risks & unknowns
- Smaller and earlier-stage than the pharma players; value is data/strain/co-development, not scale.
- Skin-microbiome program maturity is unconfirmed.
- No agri-biocontrol or biomanufacturing tie — off the lead thesis, relevant mainly to the secondary Coolvex line.
Public sources
Private-pack boundary